S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CTMX · CytomX Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
CytomX Therapeutics Inc (CTMX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.39
-0.13
(-5.35%)
● At close: October 21 at 4:00:00 PM EDT
$2.46
+0.06
(+2.50%)
Overnight:
12:58:26 AM EDT
DAY'S RANGE
$2.39
$2.39
$2.61
52-WEEK RANGE
$2.39
$2.20
$8.21
What's happening
- CTMX is down 5.35% today, trading at $2.39. — Live quote
- Volume today (212,243) is well below its 3-month average of 3,960,960. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.09 actual vs. $-0.08 estimated (-13.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CTMX
-43.66%
vs S&P 500
-57.03%
1-YEAR RETURN
CTMX
-33.61%
vs S&P 500
-48.77%
6-MONTH RETURN
CTMX
-50.21%
3-MONTH RETURN
CTMX
-27.93%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.09
Est. $-0.08
MISS -13.8%
2026-04-26 (Q1 2026)
$-0.10
Est. $-0.12
BEAT +18.8%
2026-01-26 (Q4 2025)
$-0.22
Est. $-0.10
MISS -130.4%
2025-10-26 (Q3 2025)
$-0.09
Est. $-0.05
MISS -74.4%
Valuation Measures & Ratios
Enterprise Value4$518.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)29.29
Price / Book72.70
EV4 / Revenue28.35
EV4 / EBITDA21.28
Profit Margin-435.21%
Operating Margin-476.19%
Return on Equity (ROE8)-38.46%
Return on Assets (ROA9)-30.33%
Avg Volume (3M)3,960,960
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short40,813,393
Change from Prior Settlement+5.63%
% of Float—
Days to Cover (Short Ratio)8.67
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -92.4% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -435.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -33.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CTMX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $10.3M | $6.0M | $18.7M | $50.9M | $33.4M | $25.1M | $41.5M |
| Operating income | -$23.8M | -$19.7M | -$15.8M | -$1.3M | $22.6M | $4.1M | -$8.5M | $11.7M |
| Net income | -$20.7M | -$18.2M | -$14.2M | -$154.0K | $23.5M | $5.7M | -$6.5M | $13.8M |
| Operating margin | -$1.7K | -$192 | -$264 | -$7 | $44 | $12 | -$34 | $28 |
| Net margin | -$1.5K | -$178 | -$239 | -$1 | $46 | $17 | -$26 | $33 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $381.2M | $359.4M | $151.6M | $158.3M | $175.1M | $98.5M | $120.5M | $139.0M |
| Total liabilities | $79.2M | $39.4M | $52.6M | $50.9M | $55.1M | $73.4M | $121.0M | $162.4M |
| Stockholders' equity | $302.1M | $319.9M | $99.0M | $107.4M | $119.9M | $25.0M | -$456.0K | -$23.5M |
| Total current assets | $373.2M | $353.1M | $143.9M | $149.2M | $164.6M | $86.6M | $107.3M | $124.2M |
| Total current liabilities | $39.9M | $34.0M | $46.6M | $41.0M | $39.2M | $50.2M | $85.8M | $119.2M |
| Cash & equivalents | $17.2M | $28.8M | $12.7M | $34.2M | $49.0M | $47.6M | $38.1M | $40.6M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $37.5M | $646.0K | $2.0M | $1.6M | $1.9M | $2.0M | $3.1M | $3.4M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $1.1M | $1.1M | $1.3M | $1.7M | $1.9M | $2.2M | $2.5M | $2.9M |
| Goodwill | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K | $949.0K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $31.0K | $31.0K | $31.0K | $51.0K | $56.0K | $61.0K | $66.0K | $70.0K |
| Accounts payable | $1.9M | $1.4M | $1.3M | $646.0K | $227.0K | $276.0K | $1.1M | $1.4M |
| Accrued liabilities | $12.4M | $11.9M | $14.2M | $12.4M | $11.5M | $11.4M | $12.3M | $16.7M |
| Deferred revenue (current) | $24.1M | $17.9M | $26.9M | $22.4M | $22.1M | $33.2M | $67.2M | $96.1M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $4.5M | $4.4M | $4.4M | $4.3M | $4.2M | $4.2M | $4.1M | $4.1M |
| Common stock & paid-in capital | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K |
| Retained earnings | -$750.9M | -$730.2M | -$711.9M | -$682.4M | -$668.2M | -$668.1M | -$691.6M | -$710.5M |
| Accumulated other comprehensive income (loss) | -$196.0K | $102.0K | $111.0K | $104.0K | $33.0K | -$1.0K | $27.0K | $40.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.1M | -$25.5M | -$23.2M | -$15.5M | -$15.8M | -$21.0M | -$19.9M | -$20.7M |
| Investing cash flow | $6.0M | -$192.8M | -$14.4M | $439.0K | -$76.4M | $30.6M | $15.1M | $18.2M |
| Financing cash flow | $511.0K | $234.5M | $16.6M | $253.0K | $93.5M | $0 | $2.2M | $0 |
| Free cash flow | -$18.1M | -$25.5M | -$23.4M | -$15.4M | -$15.8M | -$21.2M | -$20.0M | -$20.7M |
| Capital expenditures | $0 | $0 | $201.0K | -$127.0K | $27.0K | $119.0K | $80.0K | $19.0K |
| Share-based compensation | $2.6M | $4.7M | $1.5M | $1.4M | $1.4M | $2.0M | $1.9M | $2.0M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $36.8M | -$1.4M | $384.0K | -$240.0K | -$87.0K | -$1.1M | -$249.0K | $577.0K |
| Change in accounts payable | $571.0K | $67.0K | $655.0K | $419.0K | -$49.0K | -$804.0K | -$261.0K | $811.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M | -$116.0M |
| Net income | -$17.4M | $31.9M | -$569.0K | -$99.3M | -$115.9M |
| Operating margin | -$29 | $18 | -$6 | -$191 | -$311 |
| Net margin | -$23 | $23 | -$1 | -$187 | -$311 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Sep '22 |
|---|---|---|---|---|---|
| Total assets | $151.6M | $120.5M | $201.8M | $260.9M | — |
| Total liabilities | $52.6M | $121.0M | $249.2M | $346.6M | $307.0M |
| Stockholders' equity | $99.0M | -$456.0K | -$47.4M | -$85.8M | -$80.5M |
| Total current assets | $143.9M | $107.3M | $182.9M | $237.1M | — |
| Total current liabilities | $46.6M | $85.8M | $155.9M | $152.6M | $123.6M |
| Cash & equivalents | $12.7M | $38.1M | $17.2M | $193.7M | — |
| Accounts receivable | $2.0M | $3.1M | $3.4M | $36.0M | — |
| Property, plant & equipment | $1.3M | $2.5M | $4.0M | $5.1M | — |
| Goodwill | $949.0K | $949.0K | $949.0K | $949.0K | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $31.0K | $66.0K | $83.0K | $27.0K | — |
| Accounts payable | $1.3M | $1.1M | $1.5M | $2.8M | — |
| Accrued liabilities | $14.2M | $12.3M | $17.6M | $24.4M | — |
| Deferred revenue (current) | $26.9M | $67.2M | $132.3M | $121.3M | $87.1M |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $4.4M | $4.1M | $3.9M | $0 | — |
| Common stock & paid-in capital | $2.0K | $1.0K | $1.0K | $1.0K | — |
| Retained earnings | -$711.9M | -$691.6M | -$723.4M | -$722.9M | -$714.1M |
| Accumulated other comprehensive income (loss) | $111.0K | $27.0K | $95.0K | $10.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$75.6M | -$86.2M | -$56.0M | -$110.8M | -$119.0M |
| Investing cash flow | -$59.7M | $99.7M | -$150.7M | $98.3M | $22.5M |
| Financing cash flow | $110.4M | $7.5M | $30.2M | $648.0K | $110.2M |
| Free cash flow | -$75.8M | -$86.5M | -$56.9M | -$112.5M | -$120.6M |
| Capital expenditures | $220.0K | $310.0K | $840.0K | $1.7M | $1.6M |
| Share-based compensation | $6.3M | $7.7M | $8.6M | $13.1M | $13.2M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Change in accounts receivable | -$1.1M | -$329.0K | -$32.6M | $35.2M | -$8.0K |
| Change in accounts payable | $221.0K | -$297.0K | -$1.4M | $68.0K | -$139.0K |
| Purchases of investments | — | — | — | — | $99.9M |
| Sales/maturities of investments | — | — | — | — | $124.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CTMX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-06 to 2026-08-03
Recent transactions
- Insiders have net sold 1,624 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Carvajal Alejandra (Chief Legal Officer) — Grant / award of 100,000 shares on 2026-08-03.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)1,624 sh(1 txns)
Net Shares-1,624
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Carvajal Alejandra | Chief Legal Officer | Grant / award | 2026-08-03 | 100,000 |
| Ogden Christopher | Chief Financial Officer | Open market sale | 2026-06-15 | 1,624 |
| Chu Yu-Waye | Chief Medical Officer | Open market sale | 2026-03-17 | 21,279 |
| McCarthy Sean A. | CEO | Open market sale | 2026-03-17 | 118,969 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Open market sale | 2026-03-17 | 31,492 |
| Lester Rachael | Chief Business Officer | Grant / award | 2026-02-02 | 20,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-03 | Carvajal Alejandra | Chief Legal Officer | Grant / award | 100,000 | $0.00 |
| 2026-06-15 | Ogden Christopher | Chief Financial Officer | Open market sale | 1,624 | $3.05 |
| 2026-03-17 | Chu Yu-Waye | Chief Medical Officer | Open market sale | 21,279 | $6.42 |
| 2026-03-17 | McCarthy Sean A. | CEO | Open market sale | 118,969 | $6.42 |
| 2026-03-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | Open market sale | 31,492 | $6.42 |
| 2026-03-17 | Ogden Christopher | Chief Financial Officer | Open market sale | 19,323 | $6.42 |
| 2026-02-02 | Lester Rachael | Chief Business Officer | Grant / award | 20,000 | $0.00 |
| 2026-02-02 | Chu Yu-Waye | Chief Medical Officer | Grant / award | 75,000 | $0.00 |
| 2026-02-02 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant / award | 60,000 | $0.00 |
| 2026-02-02 | Ogden Christopher | Chief Financial Officer | Grant / award | 90,000 | $0.00 |
| 2026-02-02 | McCarthy Sean A. | CEO | Grant / award | 210,000 | $0.00 |
| 2025-11-06 | McCarthy Sean A. | CEO | Open market sale | 101,793 | $4.54 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-07-30 | 4 | 2026-07-24 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-24 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
Recent news
Headlines about CTMX (CytomX Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
CTMX Nov 2026 1.000 call (CTMX261120C00001000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-21 -
Cantor Fitzgerald reiterates USD 12 target for CytomX Therapeutics stock
AD HOC NEWS · 2026-10-20 -
CytomX Therapeutics stock closed at USD 2.28, down 5.39 percent on October 16 - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17 -
CEO exercised options and sold 101,793 CytomX Therapeutics (CTMX) shares under a trading plan.
Stock Titan · 2026-10-16 -
CytomX Therapeutics stock trades ahead of November 5 results
AD HOC NEWS · 2026-10-15 -
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha · 2026-09-14 -
CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow
Seeking Alpha · 2026-09-10 -
CytomX Therapeutics to Present at Upcoming September Investor Conferences
Yahoo Finance · 2026-09-01
No headlines in this category right now — try “All”.